At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 140 enrolled
Drug / intervention
Simvastatin +1 moredrug
Likely dose
Simvastatin 80mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Randomised, Placebo-controlled Clinical Trial of Simvastatin in Patients With Secondary Progressive Multiple Sclerosis.
In Brief
A Phase 2 clinical trial evaluating Simvastatin and Placebo for Secondary Progressive Multiple Sclerosis. Completed, enrolled 140 participants across 3 sites.
Detailed Summary
To determine whether simvastatin at a dose of 80mg can reduce the rate of whole brain atrophy, as measured by MRI, over a 2-year time-period when compared to placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSecondary Progressive Multiple Sclerosis
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2008
First PostedMar 2008
Primary CompletionNov 2011
TodayJul 2026
First PostedMar 31, 2008
Enrollment StartJan 1, 2008
Primary CompletionNov 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 18.3 years ago
Interventions
Simvastatindrug
80mg simvastatin oral once daily for 24 months
Placebodrug
Oral placebo tablet once daily for 24 months